Adipokines in hereditary breast cancer patients and healthy relatives
PDF | HTML | How to cite
Metrics: PDF 960 views | HTML 1868 views | ?
Domenico Sambiasi1,*, Simona De Summa2,*, Maria Digennaro1, Brunella Pilato2, Angelo Paradiso1,* and Stefania Tommasi2,*
1Experimental Medical Oncology, IRCCS Istituto Tumori “Giovanni Paolo II”, 70124 Bari, Italy
2Molecular Genetic Laboratory, IRCCS Istituto Tumori “Giovanni Paolo II”, 70124 Bari, Italy
*These authors contributed equally to this work
Angelo Paradiso, email: [email protected]
Keywords: adipokines, BRCA, breast cancer, BMI, hereditary
Received: May 04, 2017 Accepted: August 26, 2017 Published: September 18, 2017
Background. The role of adipocytokines and ghrelin in hereditary breast cancer syndrome (HBCS) has never been tested.
Results. No significant differences in leptin, adiponectin and ghrelin plasma levels between cancer patients and healthy subjects was observed. Conversely, an higher level of adiponectin was shown in healthy subjects with BRCA 1/2 gene mutation vs those without (p < 0.03). Logistic regression analysis demonstrated that Adiponectin plasma level (OR 0.26; 95% CI:0.007–0.81; p < 0.02) and age (OR 5.51; 95% CI:1.78–19.71; p < 0.004) were the only factors independently associated with BMI; furthermore, Leptin plasma level (OR 0.23; 95% CI:0.06–0.76; p < 0.01) and age (OR 0.05; 95% CI:0.05–0.61; p < 0.007) resulted the only factors significantly associated with breast cancer.
Materials and Methods. We analyzed blood plasma expression of leptin, adiponectin and ghrelin using Bio-Plex platform in 25 breast cancer patients with HBCS and in 38 healthy relatives. BRCA 1/2 gene status (presence of pathogenic mutations by direct molecular sequencing), clinical-pathological characteristics and Body Mass Index (BMI) of each subject were recorded.
Conclusions. Adiponectin confirms to be associated with BMI also in subjects with HBCS. Leptin plasma level seems a direct and independent biomarker of a breast cancer risk. A validation of Leptin as a circulating biomarker of breast cancer development in larger series of HBCS subjects is needed.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.